Danish dermatology specialist LEO Pharma has appointed Brian Hilberdink new executive vice president and president of LEO Pharma Inc in the USA, effective March 14, 2022. 21 February 2022
French immunotherapeutics-focussed biotech firm Transgene has appointed Steven Bloom as vice president, chief business officer with immediate effect. 10 February 2022
New Jersey-based Outlook Therapeutics, a biopharma company working to develop and launch the first approved ophthalmic formulation of bevacizumab for use in retinal indications, has announced the appointment of Joel Prieve as senior vice president, Commercial Operations. 8 February 2022
Japan’s largest drugmaker Takeda Pharmaceuticals today announced changes to its Growth and Emerging Markets Business Unit (GEM BU) leadership team as part of the company’s broader corporate leadership team changes to accelerate business growth and the delivery of transformational medicines to patients. 7 February 2022
GlaxoSmithKline’s Christine Roth is to leave the company to become the new head of the Oncology Strategic Business Unit at Bayer’s (BAYN: DE) Pharmaceuticals division. 4 February 2022
Japan’s largest drugmaker Takeda Pharmaceutical today announced changes to its executive leadership team to continue driving long-term growth in a highly competitive and dynamic global marketplace. 3 February 2022
Swiss pharma giant Roche today announced that Dr William Pao, head of Roche pharma research and early development (pRED) since 2018, has decided to leave Roche for a new opportunity and return to the USA, effective March 18, 2022. 2 February 2022
Shares of Finnish clinical-stage biopharma Faron Pharmaceutical were up 4.7% at 254 pence this morning as it announced the appointment of Juho Jalkanen as chief operating officer of the company. 31 January 2022
UK gene and cell therapy group Oxford Biomedica and US genetic medicines company Homology Medicines have agreed to establish a high-performing, full scope adeno-associated virus (AAV) manufacturing and innovation business in the USA. 28 January 2022
Replacing its retiring co-founder and chief executive Onno van de Stolpe, Belgium-based biotech Galapagos today announced that industry veteran Paul Stoffels will join the company as CEO effective April 1. 27 January 2022
Once touted as a potential successor to Merck & Co’s former boss Kenneth Frazier, Frank Clyburn is to leave his post as the company’s executive vice president and president, Human Health, to take up a role elsewhere. 21 January 2022
Austrian drug developer Marinomed Biotech today announced the appointment of Dr Cornelia Kutzer as chief business officer (CBO) of the company. 21 January 2022
New biotech company Altos Labs has launched today with the aim of unraveling the deep biology of cellular rejuvenation programming, with $3 billion fully committed from renowned company builders and investors. 19 January 2022
Polish biotech Ryvu Therapeutics has announced the appointment of Dr Hendrik Nogai to the role of chief medical officer effective February 1, 2022. 17 January 2022
German life sciences company Merck KGaA today announced new appointments in global R&D and strategy leadership for the Healthcare business sector. 13 January 2022
California-based insitro, a machine learning-driven drug discovery and development company, has announced the expansion of its leadership team. 12 January 2022
US clinical stage cell and gene therapy company Castle Creek Biosciences says it has acquired Novavita Thera, a pre-clinical gene therapy company focused on rare liver and metabolic diseases. 11 January 2022
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024